The Company was founded as a private company by scientists at Carnegie Mellon University with the help of Pittsburgh Life Sciences Greenhouse (“PLSG”) in 2008. The early years of the Company were focused on successfully discovering and formulating the PBM technology, filing for now issued patents, conducting pre-clinical experiments to provide areas of promise for accelerating and enhancing healing and conducting a First-In-Man Prospective Randomized Clinical Trial in South Africa (HEAL I) showing promising results for bone healing, soft tissue healing and infection reduction at the injured site.
Since 2016, the Company has focused on moving two product candidates from research into development, BHA and Tissue Healing Accelerant (“THA”). BHA is designed to be used in multiple bone applications, such as trauma fixation surgeries, including severe tibia fractures, spinal fusion (CT-102), foot/ankle fusion, and dental bone graft substitutes. The second product candidate, THA, expected to be used in chronic wound care and aesthetic applications, is similar in formulation to the first product candidate minus one material, β-TCP. The form of these two product candidates will feel different to the physicians/surgeons, with BHA a “putty” form (due to the β-TCP) and THA, a “paste” form. While PBM technology is initially targeted to accelerate and enhance healing in bone applications, in keeping with our exclusive license agreement, we believe PBM has the ability to deliver many regenerative factors, including the important Growth Factors directly to the area in need of enhanced tissue repair or growth, such as applications in aesthetics and wound care.